Mechanism and effect of everolimus on endometrial cancer cell RL95-2 proliferation and apoptosis / 中国综合临床

ABSTRACT

Objective To observe the effect of everolimus on proliferation,cycle and apoptosis of endometrial cancer cells and discuss the mechanism.Methods Proliferation of RL95-2 interfered with everolimus in different concentration and time was observed by MTT assay.Cell cycle and apoptosis affected by everolimus was detected by flow cytometry.PI3K-Akt-mTOR signaling pathway was detected by Western blot.Results (1) MTT assay showed that,cell viability in everolimus group was time-dependent decreased,compared with control group,there were significant differences in 48 h,72 h and 96 h ((64.36±4.78)％,(48.18±5.93) ％,(42.72±6.91) ％;F inner grouP =3.278,P＜ 0.05;F between groups =12.327,P＜ 0.01;F across groups=7.729,P＜0.05).Cell viability in everolimus group was dose-dependent decreased(F=3.264,P＜0.05).Compared with control group,RL95-2 cells in G1 phase and G2 phase was (69.28±2.61)％ and (4.75±0.84) ％,decreased in everolimus group,and in S phase (27.31±0.69) ％ was increased (t=5.743,P＜0.05;t =4.528,P＜0.05;t=6.209,P＜0.05).The apoptosis in everolimus group was 29.78％,higher than in control group (47.29％),the difference was significant (t =19.381,P＜0.01).(2) Western blot showed that both mTOR and p-Akt in everolimus group were dose-dependent decreased (F=3.589,P＜0.05;F =5.292,P＜0.05),Akt was dose-dependent increased (F =4.294,P＜0.05).Conclusion Everolimus decrease the cell viability and promote apoptosis via target inhibiting mTOR expression.